NPAideS: a drug-checking study among 3-methylmethcathinone (3-MMC) users.
Harm Reduction Journal July 28, 2023 Théo Willeman, Nathan Grundig, Christine Pochon et al. 8 citations
3-methylmethcathinone (3-MMC) has been available on the European drug market for several years, but an increase in its availability seems to have occurred around 2020, associated with reports of harm and death. We aimed to analyze the composition of the supposed 3-MMC samples purchased and its concordance with the assumed composition of the drug. A prospective multicenter (n = 6) study was...